Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in: Annals of Surgical Oncology 4/2010

01.04.2010 | Medical Oncology

The Evolving Role of Taurolidine in Cancer Therapy

verfasst von: Peter M. Neary, MB, Patrick Hallihan, MB, Jiang H. Wang, PhD, Rolf W. Pfirrmann, PhD, David J. Bouchier-Hayes, FRCS, Henry P. Redmond, FRCSI

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Background and Design

Taurolidine consists of two taurinamide rings derived from the naturally occurring amino acid taurine. It has been utilized to prevent adhesions, as an antimicrobial, and as an anti-inflammatory agent. More recently, it has been found to exert antineoplastic activity. We reviewed the literature regarding taurolidine and its role in cancer treatment.

Results and Conclusion

Taurolidine induces cancer cell death through a variety of mechanisms. Even now, all the antineoplastic pathways it employs are not completely elucidated. It has been shown to enhance apoptosis, inhibit angiogenesis, reduce tumor adherence, downregulate proinflammatory cytokine release, and stimulate anticancer immune regulation following surgical trauma. Apoptosis is activated through both a mitochondrial cytochrome-c-dependent mechanism and an extrinsic direct pathway. A lot of in vitro and animal data support taurolidine’s tumoricidal action. Taurolidine has been used as an antimicrobial agent in the clinical setting since the 1970s and thus far appears nontoxic. The nontoxic nature of taurolidine makes it a favorable option compared with current chemotherapeutic regimens. Few published clinical studies exist evaluating the role of taurolidine as a chemotherapeutic agent. The literature lacks a gold-standard level 1 randomized clinical trial to evaluate taurolidine’s potential antineoplastic benefits. However, these trials are currently underway. Such randomized control studies are vital to clarify the role of taurolidine in modern cancer treatment.
Literatur
1.
Knight B, Skellern G, Smail G, Browne M, Pfirrmann R. NMR studies and GC analysis of the antibacterial agent taurolidine. J Pharmaceut Sci. 1983;72:705–7.CrossRef
2.
Pfirrmann R. Taurolin in der Anwendung bei chirurgischen Infektionen. Chir Gastroenterol. 1991;6:131–42.
3.
Pfirrmann R, Bruckner W. Taurolin—Ein neues Konzept zur antimikrobiellen Chemotherapie chirurgischer Infektionen. Munich: Urban and Schwarzenberg; 1985. p. 3–23.
4.
Bahadir I, Oncel M, Kement M, Sahip Y. Intra-abdominal use of taurolidine or heparin as alternative products to an antiadhesive barrier (Seprafilm®) in adhesion prevention: an experimental study on mice. Dis Colon Rectum. 2007;50:2209–14.CrossRefPubMed
5.
Reith H. Therapy of peritonitis today. Surgical management and adjuvant therapy strategies. Langenbecks Arch Chir. 1997;382:S14.CrossRefPubMed
6.
Luo J, Kamata H, Karin M. IKK/NF-B signaling: balancing life and death—a new approach to cancer therapy. Am Soc Clin Invest. 2005;115:2625–32.CrossRef
7.
Marshall J, Foster D, Vincent J, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004;190:527–34.CrossRefPubMed
8.
Scevola D, Barbarini G, Marone P, Azzini M, Filice C, Bernardi R. Anti-endotoxin therapy in liver diseases. G Ital Chemioter. 1979;26:241.PubMed
9.
Görtz G. Local antiseptic and anti-endotoxin measures in intra-abdominal infections. Langenbecks Arch Chir. 1997;382:S37.CrossRefPubMed
10.
Dofferhoff A, Esselink M, de Vries-Hospers H, et al. The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes. Br Soc Antimicrob Chemother. 1993;31:373–84.CrossRef
11.
Traub W, Leonhard B, Bauer D. Taurolidine: in vitro activity against multiple-antibiotic-resistant, nosocomially significant clinical isolates of Staphylococcus aureus, Enterococcus faecium, and diverse Enterobacteriaceae. Chemotherapy (Basel). 1993;39:322–30.
12.
McCourt M, Wang J, Sookhai S, Redmond H. Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol. 2000;7:685–91.CrossRefPubMed
13.
Linder M, Ott W, Wesch G. Antibacterial therapy of purulent peritonitis: a prospective randomized study on the effects of antibiotics and taurolin, a new chemotherapeutic and antiendotoxic agent (author’s transl). Chir Forum Exp Klin Forsch. 1980:67–71.
14.
Browne M. The treatment of peritonitis by an antiseptic-taurolin. Pharmatherapeutica. 1981;2:517.PubMed
15.
Jurewitsch B, Lee T, Park J, Jeejeebhoy K. Taurolidine 2% as an antimicrobial lock solution for prevention of recurrent catheter-related bloodstream infections. J Parenter Enteral Nutr. 1998;22:242.CrossRef
16.
Reith H, Dittrich H, Haarmann W, et al. Adjuvante Therapie der Peritonitis und ihren septischen Verlaufsformen mit Taurolidin-eine prospektive randomisierte Untersuchung. Chir Gastroenterol. 1996;12:358–62.
17.
Gorman S, McCafferty D, Woolfson A, Jones D. Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with taurolin, a novel antimicrobial agent. J Appl Microbiol. 1987;62:315–20.CrossRef
18.
Blenkharn J. In-vitro antibacterial activity of noxythiolin and taurolidine. J Pharm Pharmacol. 1990;42:589–90.PubMed
19.
Erpek H, Tuncyurek P, Soyder A, Boylu S. Hyaluronic acid/carboxymethylcellulose membrane barrier versus taurolidine for the prevention of adhesions to polypropylene mesh. Eur Surg Res. 2006;38:414–7.CrossRefPubMed
20.
Tarhan O, Barut I, Sezik M. An evaluation of normal saline and taurolidine on intra-abdominal adhesion formation and peritoneal fibrinolysis. J Surg Res. 2008;144:151–7.PubMed
21.
Bedrosian I, Sofia R, Wolff S, Dinarello C. Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine. 1991;3:568.CrossRefPubMed
22.
Sendt W, Mansouri E, Schmitt-Graeff A, Wolff-Vorbeck G, Schoffel U. Influence of antiseptic agents on interleukin-8 release and transmigration of polymorphonuclear neutrophils in a human in vitro model of peritonitis. Surg Infect. 2002;3:235–44.CrossRef
23.
Rosman C, Westerveld G, Kooi K, Bleichrodt R. Local treatment of generalised peritonitis in rats; effects on bacteria, endotoxin and mortality. Eur J Surg. 1999;165:1072–9.CrossRefPubMed
24.
Rosman C, Westerveld G, Van Oeveren W, Kooi K, Bleichrodt R. Effect of intraperitoneal antimicrobials on the concentration of bacteria, endotoxin, and tumor necrosis factor in abdominal fluid and plasma in rats. Eur Surg Res. 1996;28:351–60.CrossRefPubMed
25.
Watson R, Redmond H, Mc Carthy J, Bouchier-Hayes D. Taurolidine, an antilipopolysaccharide agent, has immunoregulatory properties that are mediated by the amino acid taurine. Soc Leukocyte Biol. 1995;58:299–306.
26.
Marcinkiewicz J, Kurnyta M, Biedron R, Bobek M, Kontny E, Maslinski W. Anti-inflammatory effects of taurine derivatives (taurine chloramine, taurine bromamine, and taurolidine) are mediated by different mechanisms. Adv Exp Med Biol. 2006;583:481.CrossRefPubMed
27.
Redmond H, Leahy A, Carey J, et al. Beneficial effects of taurolidine in experimental pancreatitis. J Surg Res. 1994;56:256–60.CrossRefPubMed
28.
Chromik A, Müller A, Albrecht M, et al. Oral administration of taurolidine ameliorates chronic DSS colitis in mice. J Invest Surg. 2007;20:273.CrossRefPubMed
29.
Marcinkiewicz J, Głuszko P, Kontny E, et al. Is taurolidine a candidate for treatment of rheumatoid arthritis? Clin Exp Rheumatol. 2007;25:211.PubMed
30.
Jacobi C, Sabat R, Ordemann J, Wenger F, Volk H, Müller J. Peritoneal instillation of taurolidine and heparin for preventing intraperitoneal tumor growth and trocar metastases in laparoscopic operations in the rat model. Langenbecks Arch Chir. 1997;382:S31.CrossRefPubMed
31.
Jacobi C, Peter F, Wenger F, Ordemann J, Müller J. New therapeutic strategies to avoid intra-and extraperitoneal metastases during laparoscopy: results of a tumor model in the rat. Dig Surg. 1999;16:393–9.CrossRefPubMed
32.
Karin M, Greten F. NF- B: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–59.CrossRefPubMed
33.
Little D, Regan M, Bouchier-Hayes D. Perioperative immune modulation. Surgery. 1993;114:87–91.PubMed
34.
Da Costa M, Redmond H, Bouchier-Hayes D. Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery. J Surg Res. 2001;101:111.CrossRefPubMed
35.
Böhm B, Schwenk W, Hucke H, Stock W. Does methodic long-term follow-up affect survival after curative resection of colorectal carcinoma? Dis Colon Rectum. 1993;36:280–6.CrossRefPubMed
36.
Darnowski J, Goulette F, Cousens L, Chatterjee D, Calabresi P. Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol. 2004;54:249–58.CrossRefPubMed
37.
Daigeler A, Chromik A, Geisler A, et al. Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus. Int J Oncol. 2008;32:1205.CrossRefPubMed
38.
Wenger F, Kilian M, Braumann C, et al. Effects of taurolidine and octreotide on port site and liver metastasis after laparoscopy in an animal model of pancreatic cancer. Clin Exp Metastasis. 2002;19:169–73.CrossRefPubMed
39.
Nici L, Monfils B, Calabresi P. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. AACR. 2004;10:7655–61.
40.
Petrovic L, Schlegel K, Ries J, et al. In vitro effect of taurolidine on squamous cell carcinoma in the oral cavity. Mund Kiefer Gesichtschir. 2003;7:102.PubMed
41.
Stendel R, Stoltenburg-Didinger G, Al Keikh C, Wattrodt M, Brock M. The effect of taurolidine on brain tumor cells. Anticancer Res. 2002;22:809.PubMed
42.
Walters D, Muff R, Langsam B, Gruber P, Born W, Fuchs B. Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. Invest New Drugs. 2007;25:305–12.CrossRefPubMed
43.
Daigeler A, Brenzel C, Bulut D, et al. TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. J Exp Clin Cancer Res. 2008;27:82.CrossRefPubMed
44.
Sun B, Wang J, Liu L, Gong S, Redmond H. Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. J Surg Oncol. 2007;96:241–8.CrossRefPubMed
45.
Braumann C, Menenakos C, Atanassov V, Pfirrmann R, Guenther N, Jacobi C. Leukopoiesis is not affected after intravenous treatment with the novel antineoplastic agent taurolidine results of an experimental study in rats. Eur Surg Res. 2008;40:341–6.CrossRefPubMed
46.
Stendel R, Picht T, Schilling A, et al. Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res. 2004;24:1143–7.PubMed
47.
O’Brien G, Cahill R, Bouchier-Hayes D. Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma. Irish J Med Sci. 2006;175:10–4.CrossRefPubMed
48.
Braumann C, Winkler G, Rogalla P, Menenakos C, Jacobi C. Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case. World J Surg Oncol. 2006;4:34.
49.
Möhler T, Willhauck-Fleckenstein M, Schwartz-Albiez R, Merling A, Möhler H. Inhibition of endothelial cell adhesion and in vitro angiogenesis by Taurolidine. Cancer Therapy. 2008;6:623–8.
50.
Rodak R, Kubota H, Ishihara H, et al. Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg. 2005;102:1055–68.CrossRefPubMed
51.
Han Z, Ribbizi I, Pantazis P, Wyche J, Darnowski J, Calabresi P. The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. Anticancer Res. 2002;22:1959–64.PubMed
52.
Opitz I, Sigrist B, Hillinger S, et al. Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma. Lung Cancer. 2007;56:327–36.CrossRefPubMed
53.
Cotran R, Kumar V, Collins T, Robbins S. Robbins pathologic basis of disease. Philadelphia: WB Saunders; 1999.
54.
55.
56.
Stendel R, Scheurer L, Stoltenburg-Didinger G, Brook M, Möhler H. Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. Anticancer Res. 2003;23:2309–14.PubMed
57.
Braumann C, Schoenbeck M, Menenakos C, Kilian M, Jacobi C. Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats. Clin Exp Metastasis. 2005;22:77–83.CrossRefPubMed
58.
Susin S, Lorenzo H, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999;397:441–6.CrossRefPubMed
59.
Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-a/b signalling to p53 responses in tumour suppression and antiviral defence. Nature. 2003;424:516–23.CrossRefPubMed
60.
Crawford Y, Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 2009;335:261–9.CrossRefPubMed
61.
Braumann C, Tangermann J, Jacobi C, Mueller J, Dubiel W. Novel anti-angiogenic compounds for application in tumor therapy-COP9 signalosome-associated kinases as possible targets. Mini Rev Med Chem. 2008;8:421.CrossRefPubMed
62.
Calabresi P, Goulette F, Darnowski J. Taurolidine cytotoxic and mechanistic evaluation of a novel antineoplastic agent 1. AACR. 2001;61:6816–21.
63.
Bobrich E, Braumann C, Opitz I, Menenakos C, Kristiansen G, Jacobi C. Influence of intraperitoneal application of taurolidine/heparin on expression of adhesion molecules and colon cancer in rats undergoing laparoscopy. J Surg Res. 2007;137:75–82.CrossRefPubMed
64.
De Angelis P, Fjell B, Kravik K, et al. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int J Oncol. 2004;24:1279–88.PubMed
65.
Ota T, Maeda M, Suto S, Tatsuka M. LyGDI functions in cancer metastasis by anchoring Rho proteins to the cell membrane. Mol Carcinog. 2004;39:206–20.CrossRefPubMed
66.
Duffy S, Taylor J, Terrell J, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. CA Cancer J Clin. 2008;113:750–7.
67.
Liao W, Lin J, Wu C, et al. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res. 2008;14:428.CrossRefPubMed
68.
Heimdal J, Kross K, Klementsen B, Olofsson J, Aarstad H. Stimulated monocyte IL-6 secretion predicts survival of patients with head and neck squamous cell carcinoma. BMC Cancer. 2008;8:34.CrossRefPubMed
69.
Li B, Mao G, Cao C. Effects of inflammatory cytokines on the recurrence of liver cancer after an apparently curative operation. J Dig Dis. 2007;8:154–9.CrossRef
70.
Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-B in cancer cells converts inflammation-induced tumor growth mediated by TNF to TRAIL-mediated tumor regression. Cancer Cell. 2004;6:297–305.CrossRefPubMed
71.
Marx J. Cancer research: Inflammation and cancer: the link grows stronger. Science. 2004;306:966–8.CrossRefPubMed
72.
Pidgeon G, Harmey J, Kay E, Da Costa M, Redmond H, Bouchier-Hayes D. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer. 1999;81:1311–7.CrossRefPubMed
73.
Harmey J, Bucana C, Lu W, et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer. 2002;101:415–22.CrossRefPubMed
74.
Gong L, Greenberg H, Perhach J, Waldman S, Kraft W. The pharmacokinetics of taurolidine metabolites in healthy volunteers. J Clin Pharmacol. 2007;47:697.CrossRefPubMed
75.
Braumann C, Guenther N, Pohlenz J, Pfirrmann R, Menenakos C. Wound healing is not impaired in rats undergoing perioperative treatment with the antineoplastic agent taurolidine. Eur Surg Res. 2009;42:91–6.CrossRefPubMed
76.
Plate K, Breier G, Weich H, Mennel H, Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer. 1994;59:520–9.CrossRefPubMed
77.
Chen L, Egan L, Li Z, Greten F, Kagnoff M, Karin M. The two faces of IKK and NF-B inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nature Med. 2003;9:575–81.CrossRefPubMed
78.
Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9(1):57–63.CrossRefPubMed
79.
Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 2007;317:124.CrossRefPubMed
Metadaten
Titel
The Evolving Role of Taurolidine in Cancer Therapy
verfasst von
Peter M. Neary, MB
Patrick Hallihan, MB
Jiang H. Wang, PhD
Rolf W. Pfirrmann, PhD
David J. Bouchier-Hayes, FRCS
Henry P. Redmond, FRCSI
Publikationsdatum
01.04.2010
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0867-9

Weitere Artikel der Ausgabe 4/2010

Annals of Surgical Oncology 4/2010 Zur Ausgabe

Breast Oncology

Lymphatic Drainage Patterns from the Treated Breast

Thoracic Oncology

In Reply: Radiofrequency Ablation (RFA) of Pulmonary Metastases: Technical Success vs. Actual Benefit

Medical Oncology

Focused Microwave Thermotherapy for Preoperative Treatment of Invasive Breast Cancer: A Review of Clinical Studies

Endocrine Tumors

Occult Contralateral Carcinoma in Patients with Unilateral Papillary Thyroid Microcarcinoma

Translational Research and Biomarkers

Associations of MDM2 SNP309, Transcriptional Activity, mRNA Expression, and Survival in Stage I Non-Small-Cell Lung Cancer Patients with Wild-Type p53 Tumors

Translational Research and Biomarkers

Prevention of Local Tumor Recurrence Following Surgery Using Low-Dose Chemotherapeutic Polymer Films

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise